| Editor's Note: The Fierce PM Tracker will be taking a publication break June 19 to commemorate the U.S. Juneteenth holiday. We’ll be back in your inboxes June 20. |
|
The significant scientific capabilities of local talent, infrastructure and the island's decades of expertise fuel MBQ Pharma's advancement of innovative treatments for solid tumor cancers. Learn how your business can also impact the bioscience industry in Puerto Rico. .png)
|
|
Today’s Big NewsJun 18, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
| By Zoey Becker Following a similar move by Texas, Kansas Attorney General is accusing Pfizer of "misrepresenting" its vaccine's safety and efficacy in a 179-page civil suit seeking unspecified damages. |
|
|
|
By Conor Hale Silk Road is known as the developer of TCAR, for transcarotid artery revascularization, which reduces the risk of stroke in carotid artery procedures. |
By James Waldron The FDA has placed three trials of Zentalis’ WEE1 candidate on partial hold in the wake of two deaths that are presumed to be from sepsis. |
By Gabrielle Masson Marea Therapeutics has emerged with $190 million, a mid-stage clinical program and a plan to harness genetics and pioneer “the next frontier” of cardiometabolic medicines. |
By Ben Adams Out of the 13 pharmas vying for the top prizes at this year’s Cannes Pharma Lions, there was disappointment Monday night when just two, Biogen and Organon, walked away with a medal, and just a Bronze medal apiece at that. |
By Kevin Dunleavy Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for its third and potentially most lucrative indication—major depressive disorder. |
By Angus Liu The world’s best-selling medicine is still adding new uses, and its latest FDA approval marks a first in the cancer immunotherapy class. |
By Nick Paul Taylor Roche has added to its flotilla of RNA alliances, handing Ascidian Therapeutics $42 million upfront to use an alternative to gene editing to treat neurological diseases. The agreement includes up to $1.8 billion in milestones. |
By Nick Paul Taylor Taysha Gene Therapies has unfurled more data in the developmental disorder Rett syndrome, linking its gene therapy to improvements in the first adults and children to receive low doses of the candidate. |
By Nick Paul Taylor Barnstorming GLP-1 drugs have sent Eli Lilly and Novo Nordisk rocketing up the list of the most valuable pharma brands. The leading weight-loss players were the two big winners in the latest report by Brand Finance, which found the value of the two brands jumped by more than 50% over the past year. |
By Nick Paul Taylor Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise in ulcerative colitis, suggesting the IL-23 inhibitor can make a mark on the new indication despite the presence of rival drugs. |
By Gabrielle Masson Day One Biopharmaceuticals is offering MabCare Therapeutics up to $1.2 billion for exclusive licensing rights to an antibody drug conjugate (ADC) taking aim at solid tumors in both adults and kids. |
By Andrea Park A significant proportion of overweight or obese patients don’t find pharmaceutical ads about weight-management products relatable, nor do they look to those ads for information about managing their weight, according to a recent survey, suggesting that pharmas have a ways to go in gaining the trust of those patients. |
By Fraiser Kansteiner In the late-stage CAPItello-290 study, Truqap plus the chemotherapy paclitaxel failed to help extend the lives of patients with locally advanced or metastatic triple-negative breast cancer (TNBC) over paclitaxel and placebo alone, AstraZeneca said Tuesday. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. |
|
|---|
|
|
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
